![]() |
市场调查报告书
商品编码
1930056
全球细胞培养基市场:市场规模、占有率、成长率、产业分析、按类型、应用和地区划分的考虑因素以及未来预测(2025-2034)Cell Culture Media Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034 |
||||||
预计2025年全球细胞培养基市场规模将达30.2亿美元,2026年将达33.9亿美元。预计2034年将进一步成长至98.6亿美元,预测期内复合年增长率(CAGR)为14.27%。北美市场在2025年将占43.61%的市场占有率,这得益于其强大的生物製药研发基础设施、疫苗生产能力以及美国主要行业参与者的高度集中。传染病日益普遍促使疫苗需求快速成长,这是推动该地区市场成长的关键因素。
细胞培养基是含有促进细胞和微生物生长、维持和保存必需营养物质的固体、液体或半固体製剂。这些产品在生物製药生产中至关重要,支持疫苗生产、基因治疗和再生医学应用。由于疫苗研发和全球生产设施的扩张,COVID-19 大流行显着增加了对细胞培养基的需求。
主要市场驱动因子
疫苗生产和生物製药研发的扩张:製药公司加大对疫苗研发的投资正在推动市场成长。例如,富士胶片湾科学公司在北卡罗来纳州投资 1.88 亿美元,用于扩建其细胞培养基生产设施。干细胞疗法、再生医学和个人化疗法研发的增加进一步推动了对高品质培养基的需求。
先进细胞培养技术的应用:重组白蛋白补充剂、奈米纤维培养基和3D细胞培养平台等创新技术正在改善细胞生长、生产力和即时分析。默克集团的奈米纤维培养皿和沃特世公司的BioAccord LC-MS与Andrew+机器人联用等技术,能够更有效率地进行药物和培养基测试,进而促进细胞生长。
基因治疗和肿瘤研究的应用:细胞培养基对于基因治疗中病毒载体的扩增和癌症研究中的细胞培养至关重要。 OptiPEAK等平台可支持HEK293t细胞的生长,用于临床和商业生产。基因治疗和癌症研究在全球范围内的日益普及也推动了培养基的广泛应用。
市场限制因子
新兴国家缺乏实验室基础设施和熟练专业人员等挑战。中低收入国家往往实验室设施不足,且缺乏训练有素的技术人员,导致品质和污染问题。此外,发展中国家对动物性成分的伦理担忧以及研发投入有限,进一步限制了市场成长。
市场区隔
依类型:市场细分为传统培养基、特殊培养基、无血清培养基和其他培养基。截至2024年,传统培养基因其在基因工程、研发和基础生物学研究中的广泛应用而占市场主导地位。特殊培养基和无血清培养基因其在疫苗生产、单株抗体製造和细胞治疗的应用而呈现显着增长。
按应用:应用包括药物筛选和开发、研究和其他。药物筛选和开发是一个主要细分市场,其成长动力来自疫苗开发和用于药物测试的模拟人体生理的3D细胞培养模型。由于干细胞研究、癌症研究和先进治疗性生物製剂的开发,研究领域正在迅速扩张。
按最终用户划分:生物技术和製药行业引领市场,这主要得益于疫苗和细胞疗法监管审批的不断增加。由于全球研究项目的增多,研究实验室的市场占有率也不断扩大。
预计北美市场将在2025年达到13.2亿美元,并在2026年增长至13.8亿美元,这主要得益于对生物製药研发和疫苗生产基础设施的支持。欧洲市场预计将稳定成长,这主要得益于赛多利斯公司等企业的策略扩张以及对先进疗法的强有力的监管支持。亚太地区预计将实现最高的复合年增长率,这主要得益于生物製药研究、疫苗生产和干细胞计画的快速成长。日本、中国和印度将是该地区市场扩张的主要贡献者。
The global cell culture media market was valued at USD 3.02 billion in 2025 and is projected to reach USD 3.39 billion in 2026, eventually growing to USD 9.86 billion by 2034, reflecting a CAGR of 14.27% during the forecast period. North America dominated the market in 2025 with a 43.61% share, driven by strong biopharmaceutical research infrastructure, vaccine manufacturing capabilities, and a high concentration of key industry players in the U.S. The rapid demand for vaccines due to increasing prevalence of infectious diseases is a major factor propelling growth in the region.
Cell culture media are solid, liquid, or semi-solid formulations containing essential nutrients that simulate the growth, propagation, maintenance, and storage of cells and microorganisms. These products are critical in biopharmaceutical manufacturing, supporting vaccine production, gene therapies, and regenerative medicine applications. The COVID-19 pandemic significantly increased demand for cell culture media due to vaccine development and expansion of production facilities globally.
Key Market Drivers
Expansion of Vaccine Production and Biopharmaceutical R&D: Increasing investments by pharmaceutical companies in vaccine research and development are driving market growth. For instance, FUJIFILM Irvine Scientific invested USD 188 million in North Carolina to expand production facilities for cell culture media. Rising research into stem cell therapies, regenerative medicine, and personalized treatments is further boosting demand for high-quality culture media.
Adoption of Advanced Cell Culture Technologies: Innovations, such as recombinant albumin supplements, nano-fiber media, and 3D cell culture platforms, are improving cell growth, productivity, and real-time analysis. Technologies like Merck KGaA's nanofiber culture dishes and Waters Corporation's BioAccord LC-MS combined with Andrew+ robots facilitate more efficient drug and media testing, supporting growth.
Applications in Gene Therapies and Oncology Research: Cell culture media are essential for viral vector propagation in gene therapy and for culturing cells in cancer research. Platforms like OptiPEAK support the expansion of HEK293t cells for clinical and commercial manufacturing. Increasing gene therapy applications and cancer research initiatives globally have augmented the adoption of culture media.
Market Restraints
The market faces challenges such as insufficient laboratory infrastructure and shortage of skilled professionals in emerging nations. Low- and middle-income countries often have poorly equipped labs and lack well-trained technicians, leading to quality and contamination concerns. Ethical concerns around animal-derived components and limited R&D investments in developing countries further constrain market growth.
Market Segmentation
By Type: The market is segmented into classical media, specialty media, serum-free media, and others. Classical media dominated the market in 2024 due to extensive applications in genetic engineering, R&D, and basic biological studies. Specialty and serum-free media are witnessing strong growth due to applications in vaccine production, monoclonal antibody manufacturing, and cell therapy.
By Application: The applications include drug screening and development, research, and others. Drug screening and development is a key segment, propelled by vaccine development and 3D cell culture models that replicate human physiology for drug testing. The research segment is expanding rapidly due to stem cell studies, cancer research, and development of advanced therapeutic biologics.
By End-User: Biotechnology and pharmaceutical industries dominate the market, driven by increasing regulatory approvals for vaccines and cell-based therapies. Academic and research laboratories are also expanding their share due to the rise in global research projects.
North America had a market size of USD 1.32 billion in 2025, increasing to USD 1.38 billion in 2026, supported by biopharmaceutical R&D and vaccine manufacturing infrastructure. Europe is growing steadily due to strategic expansions by companies such as Sartorius AG and strong regulatory support for advanced therapies. Asia Pacific is projected to witness the highest CAGR, driven by rapid growth in biopharmaceutical research, vaccine production, and stem cell initiatives. Japan, China, and India are key contributors to the regional expansion.
Competitive Landscape
The market is dominated by Thermo Fisher Scientific, Danaher, FUJIFILM Irvine Scientific, BD, Merck KGaA, Sartorius AG, Corning, PromoCell, and Lonza. Key strategies include product launches, capacity expansions, mergers, acquisitions, and collaborations. For example, Lonza launched the TheraPro CHO media system in 2023, and Thermo Fisher expanded its dry powder media facility in New York in 2022 to meet global demand.
Conclusion
The global cell culture media market is poised for significant growth from 2025 to 2034, driven by increasing demand for vaccines, expansion of biopharmaceutical R&D, adoption of advanced cell culture technologies, and growing applications in gene therapy and oncology research. North America leads the market, while Asia Pacific offers the fastest growth potential. Classical media, drug screening applications, and biotechnology and pharmaceutical end-users are expected to maintain dominance. Strategic initiatives by major players and technological innovations will continue to drive market expansion, reaching USD 9.86 billion by 2034 and supporting the development of next-generation therapeutics and vaccines worldwide.
Segmentation By Type
By Application
By End User
By Region